Key result
Epidemiological characteristics and risk factors for cardiovascular damage in cancer patients were evaluated, though no quantitative results were reported in the abstract.
Why the study?
Preclinical research is limited, making it critical to comprehend the pathophysiology and epidemiological characteristics of cardiovascular disease as a consequence of anticancer therapies in cancer patients with heart disease.
Observational
This study outlines an approach to evaluate the epidemiological characteristics and risk factors for cardiovascular disease in cancer patients undergoing anticancer therapies using multimodality imaging.
In cancer patients, a cardiovascular disease (CVD) is a prevalent occurrence. When a patient has both heart disease and cancer, the treatment can be complicated because treatment for one condition can have an adverse effect on the outcome of the other. A cardiovascular disease that involves heart failures, coronary artery disease (CAD), stroke, pericardial diseases, arrhythmias, and valve and vascular dysfunction is a serious worry for long-term cancer patients. Because preclinical research is limited, it is critical to comprehend the pathophysiology of CVD as a consequence of anticancerous therapies while taking into account the developing and expanding heart. As a result, in this research, we look at the epidemiological characteristics of cancer patients who also have cardiovascular illness. Low-dose chest computed tomography, cardiac CT, and cardiac magnetic resonance imaging (MRI) are used to acquire the data and perform the screening. Chemotherapeutic drugs such as anthracyclines and trastuzumab are used to treat the condition. Univariate analysis is used to examine risk factors and predict cardiovascular damage. Sensitivity, specificity, positive predictive value, negative predictive value, life expectancy, left ventricular ejection fraction (LVEF), and longitudinal strain are among the metrics examined.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2022) conducted an observational in Cancer with cardiovascular disease. Anticancerous therapies (anthracyclines and trastuzumab) was evaluated on Cardiovascular damage (including LVEF, longitudinal strain, and life expectancy). Epidemiological characteristics and risk factors for cardiovascular damage in cancer patients were evaluated, though no quantitative results were reported in the abstract.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: